5-butyl-2-(1′,1′,1′,3′,3′,3′-hexafluoro-2′-hydroxypropan-2′-yl)-9-hydroxyphenanthridin-6(5H)-one | 1607801-50-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-butyl-2-(1′,1′,1′,3′,3′,3′-hexafluoro-2′-hydroxypropan-2′-yl)-9-hydroxyphenanthridin-6(5H)-one
• 英文别名: 5-Butyl-2-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-9-hydroxyphenanthridin-6-one；5-butyl-2-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-9-hydroxyphenanthridin-6-one
• CAS: 1607801-50-2
• 化学式: C₂₀H₁₇F₆NO₃
• 分子量: 433.35
• InChiKey: FTIWKFVIWFZGBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  60.8
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  5-butyl-2-(1′,1′,1′,3′,3′,3′-hexafluoro-2′-hydroxypropan-2′-yl)-9-hydroxyphenanthridin-6(5H)-one 、 异丙醇 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 以81 %的产率得到5-butyl-2-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-9-isopropyloxy-phenanthridin-6(5H)-one
  参考文献：
  名称：

  ANTI-SARS-COV-2 DRUG

  摘要：

  The present invention relates to an anti-SARS-CoV-2 drug including, as an active ingredient, a compound represented by formula (I): [wherein R 1 is C 1 -C 8 alkyl or the like; and R 2 -R 9 is hydrogen, halogen, hydroxyl, or Q-(C 1 -C 8 alkyl), (Q is O, NH, or S) or the like], or a pharmaceutically acceptable salt thereof.

  公开号：

  US20230192622A1
• 作为产物：
  描述：

  N-丁基苯胺 在 (氯亚甲基)二甲基氯化铵 、 palladium diacetate 、 三溴化硼 、 caesium carbonate 、 对甲苯磺酸 、 tricyclohexylphosphine tetrafluoroborate 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 10.0h， 生成 5-butyl-2-(1′,1′,1′,3′,3′,3′-hexafluoro-2′-hydroxypropan-2′-yl)-9-hydroxyphenanthridin-6(5H)-one
  参考文献：
  名称：

  Structure–activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand

  摘要：

  Retinoic acid receptor-related orphan receptors (RORs), which belong to the nuclear receptor superfamily, regulate many physiological processes, including hepatic gluconeogenesis, lipid metabolism, immune function and circadian rhythm. Since RORs resemble liver X receptors (LXRs) in the fold structure of their ligand-binding domains, we speculated that ROR-mediated transcription might be modulated by LXR ligands, in line with the multi-template hypothesis. Therefore, we screened our LXR ligand library for compounds with ROR ligand activity and identified a novel ROR ligand with a phenanthridin-6(5H)-one skeleton. Structure-activity relationship studies aimed at separating ROR inverse agonistic activity from LXR-agonistic activity enabled us to develop a series of ROR inverse agonists based on the phenanthridin-6(5H)-one skeleton, including a ROR gamma-selective inverse agonist. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.03.007

文献信息

• [EN] ANTI-SARS-COV-2 DURG<br/>[FR] MÉDICAMENT ANTI-SARS-COV-2<br/>[JA] 抗ＳＡＲＳ－ＣｏＶ－２薬
  申请人：ONCOLYS BIOPHARMA INC

  公开号：WO2021235392A1

  公开（公告）日：2021-11-25

  本発明は、 式（I）:　［式中、R1はC1～C8アルキル等、R2～R9は、水素、ハロゲン、ヒドロキシル、Q-(C1～C8アルキル)（QはO、NH若しくはSである）等］ で表される化合物又はその薬学的に許容される塩を有効成分とする抗ＳＡＲＳ－ＣｏＶ－２薬に関する。
• Structure–activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand
  作者：Yuko Nishiyama、Masahiko Nakamura、Takashi Misawa、Madoka Nakagomi、Makoto Makishima、Minoru Ishikawa、Yuichi Hashimoto

  DOI：10.1016/j.bmc.2014.03.007

  日期：2014.5

  Retinoic acid receptor-related orphan receptors (RORs), which belong to the nuclear receptor superfamily, regulate many physiological processes, including hepatic gluconeogenesis, lipid metabolism, immune function and circadian rhythm. Since RORs resemble liver X receptors (LXRs) in the fold structure of their ligand-binding domains, we speculated that ROR-mediated transcription might be modulated by LXR ligands, in line with the multi-template hypothesis. Therefore, we screened our LXR ligand library for compounds with ROR ligand activity and identified a novel ROR ligand with a phenanthridin-6(5H)-one skeleton. Structure-activity relationship studies aimed at separating ROR inverse agonistic activity from LXR-agonistic activity enabled us to develop a series of ROR inverse agonists based on the phenanthridin-6(5H)-one skeleton, including a ROR gamma-selective inverse agonist. (C) 2014 Elsevier Ltd. All rights reserved.
• ANTI-SARS-COV-2 DRUG
  申请人：ONCOLYS BIOPHARMA, INC.

  公开号：US20230192622A1

  公开（公告）日：2023-06-22

  The present invention relates to an anti-SARS-CoV-2 drug including, as an active ingredient, a compound represented by formula (I): [wherein R 1 is C 1 -C 8 alkyl or the like; and R 2 -R 9 is hydrogen, halogen, hydroxyl, or Q-(C 1 -C 8 alkyl), (Q is O, NH, or S) or the like], or a pharmaceutically acceptable salt thereof.